History

2016

January
Organovo subsidiary, Samsara Sciences, launches commercial operations

June
Organovo collaborates with UCSF to develop 3D bioprinted tissues for skeletal disease research

August
Organovo begins trading on NASDAQ Stock Market

2015

May
L’Oreal partners with Organovo to develop 3D bioprinted skin tissueJune
Organovo closes $40 million secondary public offering

October
Organovo licenses Uniquest intellectual property for kidney toxicity screening and drug development

2014

January
Organovo announces technology access collaboration with National Institutes of HealthNovember
Organovo commercially releases the exVive3D Human Liver Tissue

December
Organovo collaborates with Yale University to develop 3D organ tissues for surgical transplantation research

2013

January
Organovo and OHSU Knight Cancer Institute establish collaboration for cancer researchJuly

  • Organovo lists on NYSE MKT
  • Organovo partners with Methuselah Foundation on funding of bioprinting research

August
Organovo closes $47 million secondary public offering

November
Organovo expands headquarters facility in San Diego, CA

2012

February
Organovo goes public through a $15 million financing roundJuly
Organovo announces two issued patents: first company patent and key founder patent

December
Organovo partners with Autodesk Research to develop 3D bioprinting software

2011

March
Organovo begins corporate partnerships in drug discovery

2010

December
Organovo describes work on its fully cellular blood vessel, demonstrating ability to create novel tissues in 3D using only primary human cells

2009

January
Organovo opens laboratory in San Diego, CAAugust
Organovo awarded first NIH grant for creation of bioprinted blood vessels

September
Organovo and Invetech complete work on “Project Leeloo,” delivery of the NovoGen MMX Bioprinter

2008

July
Organovo, Inc. begins raising startup funds, leading to $3 million in angel financingNovember
First full-time employee is hired by Organovo, Inc.

2007

April
Organovo, Inc. formally incorporated in Delaware, with the intent to license the Forgacs patent suite and launch a 3D bioprinting companyAugust
Keith Murphy leaves Amgen, Inc. to begin role as full-time CEO of Organovo, Inc.

2005-06

April
Organovo founding team discusses formation of company around Forgacs organ printing technology, visits Forgacs labs in Columbia, Missouri

2004-05

Organ printing work begun at University of Missouri–Columbia. $5 million National Science Foundation Frontiers in Integrative Biological Research (FIBR) grant awarded to multi-institution team led by Professor Gabor Forgacs of the University of Missouri–Columbia. First patent application for NovoGen™ bioprinting platform filed, Self-Assembling Cell-Aggregates and Methods of Making the Same, by Forgacs, Mironov, Jakab, Neagu.

2003

Ink-jet Printing of Viable Cells patented by Dr. Thomas Boland at Clemson University